Apogee Therapeutics, Inc. (NASDAQ:APGE – Get Free Report) was down 3.7% on Friday . The company traded as low as $54.73 and last traded at $54.76. Approximately 155,024 shares were traded during mid-day trading, a decline of 70% from the average daily volume of 511,682 shares. The stock had previously closed at $56.85.
Apogee Therapeutics Price Performance
The business’s 50-day moving average price is $49.58 and its two-hundred day moving average price is $49.54. The company has a market capitalization of $3.24 billion, a price-to-earnings ratio of -10.77 and a beta of 2.74.
Apogee Therapeutics (NASDAQ:APGE – Get Free Report) last announced its quarterly earnings data on Monday, August 12th. The company reported ($0.60) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.60). As a group, research analysts predict that Apogee Therapeutics, Inc. will post -2.57 EPS for the current year.
Insider Buying and Selling at Apogee Therapeutics
Institutional Inflows and Outflows
Several institutional investors have recently modified their holdings of the stock. Arizona State Retirement System increased its holdings in shares of Apogee Therapeutics by 4.5% during the second quarter. Arizona State Retirement System now owns 5,993 shares of the company’s stock worth $236,000 after buying an additional 258 shares in the last quarter. EntryPoint Capital LLC increased its holdings in Apogee Therapeutics by 44.7% in the first quarter. EntryPoint Capital LLC now owns 1,997 shares of the company’s stock valued at $133,000 after purchasing an additional 617 shares during the period. Principal Financial Group Inc. increased its holdings in Apogee Therapeutics by 26.3% in the second quarter. Principal Financial Group Inc. now owns 6,442 shares of the company’s stock valued at $253,000 after purchasing an additional 1,340 shares during the period. China Universal Asset Management Co. Ltd. increased its holdings in Apogee Therapeutics by 28.8% in the first quarter. China Universal Asset Management Co. Ltd. now owns 7,155 shares of the company’s stock valued at $475,000 after purchasing an additional 1,600 shares during the period. Finally, Ameritas Investment Partners Inc. increased its holdings in Apogee Therapeutics by 111.2% in the first quarter. Ameritas Investment Partners Inc. now owns 4,126 shares of the company’s stock valued at $274,000 after purchasing an additional 2,172 shares during the period. 79.04% of the stock is currently owned by institutional investors and hedge funds.
Apogee Therapeutics Company Profile
Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.
Featured Articles
- Five stocks we like better than Apogee Therapeutics
- Using the MarketBeat Stock Split Calculator
- The Outlook for Interest Rate Cuts Got Blown Out of the Water
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- 3 High-Risk, High-Reward Micro-Cap Stocks You Shouldn’t Ignore
- Using the MarketBeat Dividend Yield Calculator
- 3 Bargain Stocks Positioned for Gains After Missing 2024’s Rally
Receive News & Ratings for Apogee Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apogee Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.